NASDAQ:IPXL - Impax Laboratories Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.30
+0.30 (1.20%)
Get New Impax Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPXL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Impax Laboratories in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.30.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in Impax Laboratories. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018BarclaysInitiated CoverageOverweight ➝ Overweight$27.00High
i
4/16/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$18.00 ➝ $20.00High
i
3/7/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$24.00High
i
3/2/2018Royal Bank of CanadaSet Price TargetHold$20.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
3/1/2018CowenSet Price TargetHold$21.00Medium
i
Rating by Ken Cacciatore at Cowen Inc
3/1/2018Canaccord GenuitySet Price TargetHold$19.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
3/1/2018Cantor FitzgeraldSet Price TargetBuy$35.00High
i
Rating by Louise Chen at Cantor Fitzgerald
2/22/2018Canaccord GenuitySet Price TargetHold$19.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$22.00Medium
i
Rating by A. Fadia at SVB Leerink LLC
12/18/2017Canaccord GenuitySet Price TargetHold$19.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
12/15/2017Cantor FitzgeraldSet Price TargetBuy$35.00High
i
Rating by Louise Chen at Cantor Fitzgerald
12/12/2017GuggenheimInitiated CoverageNeutral ➝ Neutral$18.00High
i
11/10/2017CowenReiterated RatingHold$16.00N/A
i
Rating by Tyler Van Buren at Cowen Inc
11/10/2017Cantor FitzgeraldBoost Price TargetOverweight$25.00 ➝ $35.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
10/30/2017UBS GroupBoost Price TargetSell$12.00 ➝ $16.00N/A
i
10/17/2017Royal Bank of CanadaSet Price TargetHold$17.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/17/2017Canaccord GenuitySet Price TargetHold$19.00N/A
i
Rating by Dewey Steadman at Canaccord Genuity
10/17/2017Cantor FitzgeraldSet Price TargetBuy$25.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
9/28/2017The Goldman Sachs GroupInitiated CoverageNeutral$20.00High
i
9/25/2017Cantor FitzgeraldReiterated RatingBuy$25.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
9/23/2017BTIG ResearchReiterated RatingBuy$20.00 ➝ $27.00Low
i
9/19/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$23.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
9/19/2017CitigroupBoost Price TargetBuy$23.00Low
i
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$17.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
9/11/2017Cantor FitzgeraldBoost Price TargetOverweight$20.00 ➝ $25.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
9/6/2017Cantor FitzgeraldReiterated RatingOverweight$20.00 ➝ $25.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/10/2017Royal Bank of CanadaSet Price TargetHold$15.00 ➝ $17.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
8/10/2017Piper Jaffray CompaniesSet Price TargetHold$17.00High
i
Rating by David Amsellem at Piper Jaffray Companies
8/9/2017Canaccord GenuitySet Price TargetHold$19.00High
i
Rating by Dewey Steadman at Canaccord Genuity
8/9/2017CowenSet Price TargetHold$12.00 ➝ $20.00High
i
Rating by Tyler Van Buren at Cowen Inc
8/9/2017Cantor FitzgeraldSet Price TargetBuy$20.00High
i
Rating by Louise Chen at Cantor Fitzgerald
7/31/2017Canaccord GenuityInitiated CoverageHold ➝ Hold$19.00High
i
Rating by Dewey Steadman at Canaccord Genuity
7/18/2017Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$9.00 ➝ $16.00Low
i
7/17/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$20.00 ➝ $21.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
7/16/2017Royal Bank of CanadaSet Price TargetHold$15.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
6/23/2017BMO Capital MarketsReiterated RatingHold$16.00Low
i
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$20.00Low
i
6/13/2017Royal Bank of CanadaReiterated RatingHold$15.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
6/12/2017Janney Montgomery ScottReiterated RatingNeutral$21.00High
i
5/11/2017Royal Bank of CanadaReiterated RatingOutperform$10.00 ➝ $62.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
4/11/2017Royal Bank of CanadaReiterated RatingSector PerformLow
i
Rating by Randall Stanicky at Royal Bank of Canada
4/8/2017Royal Bank of CanadaSet Price TargetHold$10.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
4/5/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$11.00 ➝ $15.00High
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
4/2/2017Royal Bank of CanadaReiterated RatingSector Perform$10.00Low
i
3/27/2017GuggenheimReiterated RatingBuy$20.00Low
i
3/8/2017Susquehanna BancsharesDowngradePositive ➝ Neutral$18.00 ➝ $10.00Low
i
3/8/2017UBS GroupDowngradePositive ➝ NeutralN/A
i
Rating by Marc Goodman at UBS Group AG
3/8/2017Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$11.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
3/2/2017Royal Bank of CanadaLower Price TargetSector Perform$15.00 ➝ $10.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
3/1/2017Piper Jaffray CompaniesDowngradeNeutral ➝ Underweight$7.00N/A
i
1/17/2017Royal Bank of CanadaReiterated RatingSector PerformN/A
i
Rating by Randall Stanicky at Royal Bank of Canada
1/13/2017BMO Capital MarketsReiterated RatingSell ➝ Market Perform$18.00N/A
i
1/3/2017Royal Bank of CanadaReiterated RatingHold$15.00N/A
i
12/28/2016Janney Montgomery ScottInitiated Coverageinit ➝ Neutral$15.00N/A
i
12/23/2016Deutsche Bank AktiengesellschaftReiterated RatingHold$17.00N/A
i
11/14/2016WallachBeth CapitalDowngradeBuy ➝ Hold$30.00 ➝ $18.00N/A
i
11/11/2016UBS GroupSet Price TargetSell$12.00N/A
i
Rating by Marc Goodman at UBS Group AG
11/10/2016Royal Bank of CanadaReiterated RatingSector Perform$30.00 ➝ $18.00N/A
i
11/10/2016Royal Bank of CanadaLower Price TargetSector Perform$30.00 ➝ $18.00N/A
i
11/7/2016Bank of AmericaDowngradeNeutral ➝ Underperform$19.00N/A
i
9/27/2016The Goldman Sachs GroupUpgradeSell ➝ Neutral$25.00 ➝ $26.00N/A
i
Rating by Gary Nachman at The Goldman Sachs Group, Inc.
8/15/2016Northland SecuritiesUpgradeMarket Perform ➝ Outperform$30.00N/A
i
8/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$40.00 ➝ $32.00N/A
i
8/11/2016Royal Bank of CanadaReiterated RatingSector Perform$35.00 ➝ $30.00N/A
i
8/10/2016Deutsche Bank AktiengesellschaftLower Price TargetHold$31.00 ➝ $24.00N/A
i
8/10/2016SVB LeerinkLower Price TargetMarket Perform$33.00 ➝ $24.00N/A
i
8/10/2016WallachBeth CapitalLower Price TargetBuy$40.00 ➝ $30.00N/A
i
8/10/2016Royal Bank of CanadaLower Price TargetSector Perform$35.00 ➝ $30.00N/A
i
7/6/2016SVB LeerinkReiterated RatingMarket Perform$31.00 ➝ $33.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
6/28/2016BMO Capital MarketsInitiated CoverageMarket Perform$30.00N/A
i
6/22/2016Piper Jaffray CompaniesReiterated RatingOverweight$41.00 ➝ $40.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
6/22/2016UBS GroupReiterated RatingSell$28.00N/A
i
Rating by Marc Goodman at UBS Group AG
6/22/2016SVB LeerinkReiterated RatingMarket Perform$31.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
6/22/2016Deutsche Bank AktiengesellschaftLower Price TargetHold$42.00 ➝ $31.00N/A
i
6/21/2016Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
i
(Data available from 6/14/2016 forward)
Impax Laboratories logo
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
Read More

Today's Range

Now: $18.30
$17.40
$18.95

50 Day Range

MA: $18.30
$18.30
$18.30

52 Week Range

Now: $18.30
$13.05
$25.70

Volume

3,041,017 shs

Average Volume

945,265 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Impax Laboratories?

The following Wall Street sell-side analysts have issued reports on Impax Laboratories in the last twelve months:
View the latest analyst ratings for IPXL.

What is the current price target for Impax Laboratories?

0 Wall Street analysts have set twelve-month price targets for Impax Laboratories in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Impax Laboratories in the next year.
View the latest price targets for IPXL.

What is the current consensus analyst rating for Impax Laboratories?

Impax Laboratories currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IPXL.

What other companies compete with Impax Laboratories?

How do I contact Impax Laboratories' investor relations team?

Impax Laboratories' physical mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company's listed phone number is (908) 947-3120 and its investor relations email address is [email protected] The official website for Impax Laboratories is www.impaxlabs.com.